IPP Bureau
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
By IPP Bureau - November 05, 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Imtiyaz Basade appointed Senior VP of NATCO Pharma
By IPP Bureau - November 05, 2024
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Gland Pharma posts Q2 FY25 consolidated profit at Rs. 163.53 Cr
By IPP Bureau - November 05, 2024
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics
By IPP Bureau - November 05, 2024
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Emcure Pharma forms subsidiary to strengthen dermatology portfolio
By IPP Bureau - November 04, 2024
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
By IPP Bureau - November 04, 2024
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Briefs: Sun Pharmaceutical Industries and Biocon Biologics
By IPP Bureau - November 04, 2024
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
By IPP Bureau - November 02, 2024
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America
By IPP Bureau - November 02, 2024
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
UPM, Selenis and Bormioli Pharma introduce the world's first pharmaceutical bottle partially made with wood-based plastics
By IPP Bureau - November 02, 2024
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Lupin to develop inhalers with near-zero global warming potential propellants
By IPP Bureau - November 01, 2024
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
AbbVie to acquire Aliada Therapeutics
By IPP Bureau - November 01, 2024
Strengthening focus in Alzheimer's disease and neuroscience pipeline
AstraZeneca China President currently under investigation
By IPP Bureau - November 01, 2024
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
By IPP Bureau - November 01, 2024
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
